SCHEMBL330276

SCHEMBL330276

OB(O)c1ccc(CNCCSC(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 7/20 0.52
KIF11 P52732 5/20 0.45
TRPV1 Q8NER1 5/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17933728 0.85 SIRT2 (0.63) SIRT2KIF11MEN1KMT2ATDP1
SCHEMBL1906153 0.77 SIRT2 (0.63) SIRT2KIF11
SCHEMBL6356134 0.75 TRPV1 (0.58) TRPV1MEN1KMT2ATDP1
SCHEMBL330275 0.70 TRPV1 (0.37) TRPV1MEN1KMT2ATDP1
SCHEMBL3979565 0.69 LPL (0.57) TRPV1MEN1KMT2A
SCHEMBL330333 0.69 LPL (0.45) TRPV1MEN1KMT2ATDP1
SCHEMBL974722 0.68 KIF11 (0.63) KIF11
SCHEMBL20043060 0.67 SIRT2 (0.52) SIRT2KIF11
SCHEMBL14962372 0.67 SIRT2 (0.52) SIRT2KIF11
SCHEMBL974918 0.67 SIRT2 (0.49) SIRT2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1292709-B1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS EIDGENOESS TECH HOCHSCHULE (CH) 2012-01-18 EP disclosed
US-7291673-B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2007-11-06 US disclosed
EP-1292709-A4 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS EIDGENOESS TECH HOCHSCHULE (CH) 2004-09-22 EP disclosed
US-20030220245-A1 Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2003-11-27 US disclosed
EP-1292709-A1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS Eidgenössische Technische Hochschule Zürich (CH) 2003-03-19 EP disclosed
WO-2001092584-A1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220245-A1 Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds PAICS, C9, LIPA SIRT2 4197/4885KIF11 2222/4885TRPV1 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.